Trial Profile
Imatinib Mesylate Therapy in Systemic Mastocytosis Patients Lacking KIT Mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib
- Indications Mastocytosis
- Focus Therapeutic Use
- 26 Aug 2016 Status changed from active, no longer recruiting to completed.
- 22 Apr 2015 Planned end date changed from 1 Jun 2012 to 1 Aug 2015 as reported by ClinicalTrials.gov
- 29 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.